Jeffrey B. Smerage
Biochemistry, Genetics and Molecular Biology · University of Michigan
Established · publishing since 1996Rising activity
Cancer Genomics and DiagnosticsCancer Cells and MetastasisBreast Cancer Treatment StudiesCancer Treatment and PharmacologyAdvanced Breast Cancer Therapies
Publications
67
Citations
2,841
Est. group size
—
Recurring co-author estimate
Active years
30
Publishing since 1996
In context
Among 1,668 established Biochemistry, Genetics and Molecular Biology PIs within our index
Citations: 2,841p25 1,237 · p75 8,666 · cohort median 3,422
Publications / year (recent): 4.4p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~43 · 3% small-team papers (≤3 authors) · across 10 venues
Publication cadence
Publications per year over the last 10 years — averaging 4.4/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Clinical Cancer Research · 2025
- Supplementary Methods S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Table S7 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Table S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Table S5 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Table S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Figure S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Table S2 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Table S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Figure S1 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Table S6 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Table S9 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Figure S4 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Data from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
- Supplementary Figure S3 from Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
2025
Publishes in
- Journal of Clinical Oncology×4
- JCO Oncology Practice×2
- Clinical Cancer Research×2
- JNCI Journal of the National Cancer Institute×1
- Pharmacogenomics×1
Similar researchers
By research-topic overlap
- Sarah Owen
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Katherine Broderick
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Kirk Herman
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Arvind Rao
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Daniel G. Stover
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile